These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25044535)

  • 1. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial.
    Montero-Perez-Barquero M; Flather M; Roughton M; Coats A; Böhm M; Van Veldhuisen DJ; Babalis D; Solal AC; Manzano L
    Eur J Heart Fail; 2014 Sep; 16(9):1009-15. PubMed ID: 25044535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial.
    Dobre D; van Veldhuisen DJ; Mordenti G; Vintila M; Haaijer-Ruskamp FM; Coats AJ; Poole-Wilson PA; Flather MD;
    Am Heart J; 2007 Jul; 154(1):109-15. PubMed ID: 17584562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS.
    Mulder BA; van Veldhuisen DJ; Crijns HJ; Böhm M; Cohen-Solal A; Babalis D; Roughton M; Flather MD; Coats AJ; Van Gelder IC
    Eur J Heart Fail; 2012 Oct; 14(10):1171-8. PubMed ID: 22764183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]).
    de Boer RA; Doehner W; van der Horst IC; Anker SD; Babalis D; Roughton M; Coats AJ; Flather MD; van Veldhuisen DJ;
    Am J Cardiol; 2010 Jul; 106(1):78-86.e1. PubMed ID: 20609652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study.
    von Haehling S; van Veldhuisen DJ; Roughton M; Babalis D; de Boer RA; Coats AJ; Manzano L; Flather M; Anker SD
    Eur J Heart Fail; 2011 Jun; 13(6):656-63. PubMed ID: 21613429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
    Flather MD; Shibata MC; Coats AJ; Van Veldhuisen DJ; Parkhomenko A; Borbola J; Cohen-Solal A; Dumitrascu D; Ferrari R; Lechat P; Soler-Soler J; Tavazzi L; Spinarova L; Toman J; Böhm M; Anker SD; Thompson SG; Poole-Wilson PA;
    Eur Heart J; 2005 Feb; 26(3):215-25. PubMed ID: 15642700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
    Germino FW; Lin Y; Pejović V; Bowen L
    Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial.
    Lewin A; Lasseter KC; Dong F; Whalen JC
    J Am Soc Hypertens; 2012; 6(3):228-36. PubMed ID: 22421631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nebivolol on biomarkers in elderly patients with heart failure.
    Taneja AK; Gaze D; Coats AJ; Dumitrascu D; Spinarova L; Collinson P; Roughton M; Flather MD;
    Int J Cardiol; 2014 Aug; 175(2):253-60. PubMed ID: 24877590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy.
    Ghio S; Magrini G; Serio A; Klersy C; Fucili A; Ronaszèki A; Karpati P; Mordenti G; Capriati A; Poole-Wilson PA; Tavazzi L;
    Eur Heart J; 2006 Mar; 27(5):562-8. PubMed ID: 16443607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial.
    Lewin A; Punzi H; Luo X; Stapff M
    Clin Ther; 2013 Feb; 35(2):142-52. PubMed ID: 23332366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
    Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol for the treatment of heart failure.
    Riva N; Lip GY
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1733-46. PubMed ID: 21980961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systolic blood pressure and mortality in patients with atrial fibrillation and heart failure: insights from the AFFIRM and AF-CHF studies.
    Tremblay-Gravel M; Khairy P; Roy D; Leduc H; Wyse DG; Cadrin-Tourigny J; Macle L; Dubuc M; Andrade J; Rivard L; Guerra PG; Thibault B; Ahmed A; Talajic M; Guertin MC; White M
    Eur J Heart Fail; 2014 Nov; 16(11):1168-74. PubMed ID: 25296634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.